ATRC — AtriCure, Inc.
Is ATRC overbought or oversold? Here is the current MarketMoodz read.
AtriCure, Inc. (ATRC) currently reads Oversold on the MarketMoodz overbought/oversold meter, as of November 17, 2026. The Healthcare name (Medical Instruments & Supplies) last closed at $55.02. The rating moved from Strong Oversold to Oversold on November 16, 2026.
- Public ratingOversold (as of November 17, 2026)
- Last close$55.02
- Last changeMoved from Strong Oversold to Oversold on November 16, 2026
- SectorHealthcare
- IndustryMedical Instruments & Supplies
See all oversold Healthcare stocks →
AI analysis
AtriCure is positioned as a specialist in surgical AF management and LAA occlusion with recurring consumable revenues and a meaningful installed base. The expanding addressable market from broader OR modernization (including growth in surgical robotics) and demographic trends supports upside for procedure volumes. However, competition from large medtech and catheter-based alternatives, reimbursement/regulatory pressure, and execution risks for international scale and profitability drive material near-term uncertainty. Monitor procedural growth metrics, margin trajectory, and any clinical/regulatory developments as primary drivers of the next several quarters.
Key factors
- Focused franchise in surgical atrial fibrillation (AF) management and left atrial appendage (LAA) occlusion with established procedure-level adoption among cardiac surgeons
- Recurring consumables and disposable revenue tied to procedural volume provide high gross-margin, annuity-like sales
- Demographic tailwinds: aging population and rising AF prevalence support long-term addressable market growth
- Surgical robotics expansion into general surgery increases OR modernization and may expand hospital willingness to adopt complementary surgical devices
- Improving revenue and margin trends as commercial execution scales (broader installed base and international expansion potential)
- Favorable near-term market tone with selective growth-stock support could help sentiment for medtech names
Risks
- Competition from large-cap medtech and catheter‑based ablation competitors (Medtronic, Abbott and EP-focused players) that can pressure pricing and market share
- Reimbursement and payor/regulatory pressure (including Medicare/Medicare Advantage integrity actions) that could constrain hospital procedure economics
- Clinical adoption shifts toward less‑invasive catheter approaches or alternate technologies reducing surgical AF case volumes
- Execution risk around international expansion, commercial scale, and margin improvement milestones
- Small‑cap volatility and limited liquidity which can amplify downside on negative news
- Regulatory/clinical data risk or product-related safety events that could delay adoption or trigger recalls
See today's live rating, score and targets
Members see the live hourly rating for ATRC — the numeric AI score plus targets and entry zones — while this public page updates nightly.
Start the 14-day trialThis page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.